Posters

Comparison between ganciclovir 0.15% eye gel and acyclovir 3% eye ointment for the treatment of acute herpetic corneal ulcers

Poster Details

First Author: A.Gad EGYPT

Co Author(s):                        

Abstract Details

Purpose:

A prospective clinical trial study was done on 20 patients presenting to Sohag University ophthalmic out clinic with acute epithelial viral keratitis. The aim to assess the efficacy and tolerability of ganciclovir 0.15% eye gel and acyclovir 3% eye ointment for the treatment of acute herpetic corneal ulcers

Setting:

Sohag University hospital

Methods:

A prospective clinical trial study was done on 20 patients presenting to Sohag University ophthalmic out clinic with acute epithelial viral keratitis.All patients exposed to full ophthalmological examination particularly slit lamp with flourescein stain, we divide them on 2 groups, the first was given acyclovir 3% eye ointment five times a day , the second was given ganciclovir 0.15% ophthalmic gel five times a day. The patients are followed on 3rd, 7th and 14 th days for recording efficacy and tolerability. The efficacy as healing of the ulcer and tolerability regarding blurred vision, eye irritation, punctate keratitis, and conjunctival hyperemia.

Results:

the first group 10 patients, 7 males and 3 females, the mean age was 54.00�Â�±14.60. right eye affected in 6 patients and left in 4 , all patients showed complete epithelial healing after 14 days but with poor tolerability with blurred vision(4patients), eye irritation(5 patients) and hyperemia(2 patients). second group6 males and 4 females, the mean age was 46.90�Â�±13.65. right eye affected in 7 patients and left in 3 , all patients showed complete epithelial healing after 14 days but with less complaints. P value regarding improvement(1.000) and regarding duration of healing(0.353) between 2 groups is not statistically significant.

Conclusions:

Herpetic keratitis is a major cause of visual disability, ganciclovir 0.15% gel is effective as acyclovir 0.3% ointment in the treatment of epithelial herpetic keratitis, safe and well tolerated so increasing the patient compliance.

Financial Disclosure:

NONE